Background: Monitoring mental health treatment outcomes for populations requires an understanding as to which patient information is needed in electronic format and is feasible to obtain in routine care.
I ncreasingly, health policy is focused on using electronic health information to help reduce unnecessary costs and improve outcomes through improved clinical information sharing. [1] [2] [3] [4] To succeed in improving quality and outcomes across a system of care, the electronic data gathered must be clinically useful for predicting outcomes and must be financially feasible to obtain. Administrative datasets are often used for quality assessment because they are financially feasible to obtain across a system of care, but they are limited in clinical detail. Several large healthcare organizations are pioneering in the use of electronic medical record data, generated during routine care, as feasible and important components of quality assessment and population health management. [5] [6] [7] However, this requires heavy investment in information technology by the organization. An additional challenge for routine quality assessment is that mostly usual care is provided in fragmented provider systems that lack comprehensive healthcare and outcomes data. Health Information Exchanges are one proposed solution to develop a universal database of the clinical health and healthcare of a population, in an attempt to overcome these barriers.
In these early stages of developing new infrastructure to electronically manage population health, deciding which or how much information should be extracted electronically across systems of care is an important step in achieving routine quality assessment. For mental health treatment, no existing research provides guidance as to how much detail regarding patient or treatment characteristics is needed to accurately predict outcomes. Therefore, it is important to determine whether clinically limited but easily obtained data can be used to discriminate outcomes.
We examine this question using observational data from the National Institute of Mental Health funded Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Bipolar disorder is a prevalent, disabling, and deadly illness [8] [9] [10] [11] [12] affecting an estimated 2.6% of the United States adult population. 13 It is characterized by elevated mood states, which can impair function and judgment, and frequently treatment-resistant depressions. No contemporary longitudinal follow-up study examines whether bipolar disorder outcomes can be predicted.
The goal of the STEP-BD observational study arm was to study outcomes in a demographically and clinically heterogeneous bipolar population. STEP-BD patients, providers, and treatment processes are a "middle ground" between usual care and clinical research. The participating STEP-BD clinics were often located in academic medical centers but community provider clinics were included as well. The bipolar diagnoses were established through structured clinical interviews (unlike usual care), but cooccurring psychiatric diagnoses and other clinical information were obtained through a semistructured assessment in which Diagnostic and Statistical Manual of Mental Disorders, 4th Edition criteria were not enumerated. In addition, although the providers received additional education about treating bipolar disorder, decisions by the treating psychiatrists were not constrained. 14 In this study, STEP-BD observational data are used to construct 2 sets of models. In one, we use the detailed clinical information to predict remission rates. We compare these results to a second model in which the clinical detail is limited to information typically seen in administrative billing files. Our aims are 2-fold: (1) to determine the accuracy of clinical registry data to serve as a "gold standard" for predicting bipolar disorder outcomes and (2) to determine whether demographically and clinically limited data, similarly limited in scope to information that already exists in administrative billing data, can adequately predict bipolar disorder outcomes. If so, then this study can provide valuable guidance from a health policy perspective regarding patient characteristics that can feasibly be captured electronically across a system of care for outcomes assessment.
METHODS

Data Source and Population
STEP-BD sites were selected from formal applications based on their capacity to deliver care to bipolar disorder patients (demonstrated by having bipolar specialty programs that actively provided care to at least 100 patients) and adequate computer and telecommunication infrastructure to comply with the secure web-based data-entry system. Sites were then further selected based on demographic diversity and geographic balance. Applicant sites were given preference if they had experience in conducting clinical research with patients. Nineteen STEP-BD sites were recruited from across 12 states. In addition, several STEP-BD academic sites partnered with local clinics (6 partnerships in 5 cities) to further increase participation of usual care, community clinics. 15 Study participants gave informed consent and institutional review board approval was obtained at each site. Further institutional review board approval was obtained by the McLean Hospital and Harvard Medical School for this analysis.
In the STEP-BD naturalistic arm, all participants received baseline and quarterly assessments for the first year.
The baseline diagnostic assessment was completed by the treating psychiatrist using a semistructured format assessment tool, the Affective Disorders Evaluation (ADE). In the ADE, mood disorders were diagnosed using a modified version of the Structured Clinical Inventory Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Axis I Disorders mood modules. No other potentially comorbid psychiatric disorder had a structured diagnostic format. Medical comorbidity information was obtained through patient self-reports, including the patient reported presence of a seizure disorder. The treating psychiatrist detailed changes in affective symptoms, medications, and adherence to medications in scheduled and unscheduled follow-up visits using a structured form (Care Monitoring Form).
Several baseline and quarterly assessments were conducted by STEP-BD study personnel, independent of the treating psychiatrist. The treating psychiatrists were blind to the results of these assessments, which included the Mini-International Neuropsychiatric Interview (MINI) at baseline 16 ; baseline and quarterly Young Mania Rating Scale (YMRS), 17 Montgomery-Asberg Depression Rating Scale (MADRS) 18 ; and patient self-report of their mental health services use over the prior 3 months. Baseline demographic information was obtained by trained research assistants
We included all STEP-BD patients who entered the study between 2000 and 2004 (N = 3168).
Primary Outcome
Our primary outcome of interest was euthymia/remission, defined if YMRS score of <4 and MADRS score <5, which was measured at each quarterly follow-up. Although these thresholds are lower than those typically seen in the literature, research has shown that they correspond to a global clinical measure of remission for patients with bipolar disorder. 19 We also examined YMRS <7 and MADRS <10 as an alternative, less stringent cutoff that allows some minimal symptoms and has some support in the literature as well. 20, 21 We selected the prediction of euthymia at 1 year as our primary analysis as it is meaningful both from a clinical and health policy/quality assessment perspective.
Explanatory Variables
We fit 2 separate models: a "gold standard" model that contained a richer clinical detail and a second, modified model containing variables of limited demographic and clinical detail, henceforth denoted the "limited-detail" model. Covariates thought to be correlated with symptom severity, treatment complexity, or remission were chosen based on clinical knowledge and the prior literature (Table 1) . Both models included self-report explanatory variables for baseline data describing study entry year, age (as a continuous variable), sex, race/ethnicity, insurance type, and the presence of a comorbid seizure disorder. Also included in the model was time-varying information on treatment characteristics during the longitudinal study period, such as medications prescribed and mean mental health visits (inpatient, outpatient, or emergency room) during the 3 months before each visit, and patient self-report of adherence with antimanic medication.
Both models included explanatory variables for bipolar disorder type (bipolar I/schizoaffective disorder, bipolar II, and other bipolar spectrum disorders) and specific comorbid psychiatric illnesses (or their pharmacologic treatment) that can worsen the course of bipolar disorder. These include substance use disorders (SUDs), anxiety disorders, and attention-deficit hyperactivity disorder (ADHD). However, comorbid diagnostic information for the gold standard model was obtained through the MINI, whereas for the limiteddetail model, it was obtained from the less structured ADE (where psychiatrists were prompted to "use DSM criteria for nonmood diagnoses, but not provided the criteria), as a better approximation of usual care diagnoses than the MINI. Of note, we included only current SUD ascertained by the MINI in the gold standard model because a current SUD would be more reliably detected in routine clinical assessments than a past SUD, and is more clinically relevant to bipolar outcomes. However, the ADE did not distinguish between current versus past SUD.
The "gold standard" model included some baseline nontime varying information not routinely found in administrative data and so was excluded from the limited-detail model. These characteristics were clinical history variables (history of psychosis, legal problems or violence, suicide attempt), the Bipolarity Index, 22 and a baseline past month Global Assessment of Functioning (GAF). 23 The Bipolarity Index contains 5 categories that describe the characteristics of prior bipolar episodes, age of onset, illness course, treatment response, and family history. The score ranges from 0 to 100, higher scores indicate characteristics most consistent with bipolar disorder. The GAF is a commonly used measure of clinical symptoms and functioning, and ranges from 0 to 100. Higher GAF scores indicate fewer symptoms/higher functioning.
Finally, time, measured as days since baseline, was included as a continuous explanatory variable in both models to capture longitudinal trends. We also included time in both models to permit nonlinear trends in the log odds of remission.
Statistical Analysis
Our analyses involved several steps. As some covariates were missing for some subjects, we multiply imputed missing values. Our findings are based on combined multiply imputed datasets. We conducted bivariate tests to compare remission rates at baseline and the 1-year follow-up by sample characteristic. These included w 2 tests among categorical variables and Wilcoxon rank sum tests for continuous variables. Next, we estimated the gold standard model using longitudinal random-effects regression models using a developmental sample consisting of a random sample of 80% of our participants. Using the developmental sample, we identified predictors and their functional form in the regression model. Model overfitting indices 24 and areas under the receiver operating characteristic (ROC) curves (AUCs) were computed using a validation sample that was composed of the remaining 20% of participants. We next estimated a random-effects regression model using the variables containing limited detail. We compared the predictive accuracy of the gold standard and limited-detail models to address our primary question of interest.
Missing Data
We examined the frequency of missing responses at baseline and at each quarterly follow-up. Observations measured at baseline and quarterly visits were used to predict remission based on the composite outcome of MADRS <5 and YMRS <4 at approximately 1 year after study entry. As some explanatory variables had missing values, we used multiple imputation techniques to fill in missing values for baseline covariates, referred to as "item" nonresponse. This was accomplished using the SAS (version 9.2) macro, "IVEWare," that uses sequential imputation techniques. 25 No values were imputed for missing outcomes (ie, for those lost to follow-up). Five "completed" datasets were generated for analyses. All analyses were based on combining test statistics or regression estimates from the 5 completed datasets using the SAS procedure MIANALYZE.
Model Development and Analysis Gold Standard Model
We used the developmental dataset to build a predictive, but parsimonious "gold standard" model. We included both random intercepts and random time (measured in days) effects for each subject to permit heterogeneity in patient baseline rates and in remission trajectories. We refined the model through elimination of predictors not statistically significant at the a = 0.05 level. Once we were satisfied with model fit, we assessed the fit and accuracy of the gold standard model using the validation sample.
Prediction accuracy was measured in multiple ways. First, we estimated the area under the ROC curve, in which AUCs Z0.80 are considered clinically useful. 24 Second, we categorized the predicted remission rates in the validation sample into deciles, and compared the observed and predicted remission rates within each decile. Observed and predicted rates that are close within a decile indicate that the model is highly predictive for that particular range. As a final step, we estimated the random-effects regression models to the combined validation and developmental samples to provide readers with the final regression parameter estimates and their corresponding standard errors.
Overfitting statistics were assessed by computing the linear predictor for each participant in the validation sample, using the regression parameter estimates from the developmental sample, and then observed covariates of participants in the validation sample. We regressed observed remission status of the validation participants on their linear predictor score. An estimated intercept close to 0 and an estimated coefficient of the linear predictor score close to 1 from this regression reflects little model overfitting.
Limited-Detail Model
We modified the variables in the gold standard model to approximate variables typically found in administrative data, and estimated the longitudinal random effects regression model. We compared the gold standard and limiteddetail models by testing for differences in the AUCs for the validation samples. This test accounted for the correlation induced by the same participants appearing in the gold standard and limited-detail models.
Additional Analyses
We repeated the above steps of calculating the AUCs, comparing observed and predicted outcomes, and estimating overfit indices to the alternative, less stringent clinical outcome that included mild symptoms (ie, MDRS<10, YMRS<7). Finally, because comorbid anxiety, ADHD, and SUD were determined by different diagnostic methods in the gold standard and limited-detail models, we also examined the degree of concordance between the 2 diagnostic methods.
RESULTS
Among the 3168 participants, representing 9181 person-observations, missing item response rates ranged from 0% to 3.2%. There was significant attrition of the study population over the course of the year with only 17.2% of the participants completing follow-up 4 ( Table 1) . Approximately, 26% were in remission at the 1-year follow-up compared with 12.3% at baseline. Comorbid mental health diagnosis frequencies varied based on whether they were ascertained through the ADE or MINI. The prevalence of comorbid anxiety disorders was similar across the 2 diagnostic methods (eg, 33.6% vs. 37.9% at baseline). However, ADE interviews by the treating psychiatrists yielded half as many ADHD diagnoses (4.6% vs. 9.0% at baseline) and nearly double the SUD diagnoses (35.2% vs. 16 .9% at baseline) as the MINI interview conducted by the clinical research specialist. Bivariate analyses of these 2 diagnostic methods found 80.1% concordance for anxiety disorders, 73.2% for SUD, and 93.5% for ADHD.
In bivariate analyses, variables suggestive of more complicated or severe illness (eg, psychosis, legal problems/ violence, history of suicide attempt, lower GAF score), or the presence of comorbid medical or mental health conditions, were associated with a lower probability of remission at baseline ( Table 2 ). Although this finding was not consistently observed at follow-up 4 (ie, the 1-year follow-up) there were considerably fewer people at this follow-up, making it difficult to draw firm conclusions. It is also notable that prescribing adjunctive medications (eg, antidepressants, benzodiazepines) was associated with a lower probability of remission at both baseline and follow-up 4, suggesting that these patients likely had a more complicated and treatment-resistant course.
The random-effects logistic regression analyses indicated no overfitting in the validation sample using the goldstandard model [intercept = 0.12 (SE = 0.11) slope = 0.97 (SE = 0.99)]. In the validation sample, the gold standard model AUC (95% confidence interval) was 0.80 (0.74 to 0.86) at baseline; and 0.71 (0.64 to 0.86) at 1-year follow-up. The limited-detail model had statistically significantly lower accuracy at baseline compared with the gold standard model [baseline = 0.67 (0.60 to 75), correlated ROC P = 0.0002]; but not at 1-year follow-up [AUC = 0.67 (0.54 to 0.80); correlated ROC P = 0.090] (Figs. 1A, B ). The gold standard and administrative models performed similarly in the clinical subpopulations as they did in the full validation sample. The gold standard model exhibited better agreement between observed and predicted decile values for remission than the limited-detail model ( Figs. 2A, B ). The poorest agreement between observed and predicted full remission rates occurred with the limited-detail model at 1 year.
The AUC and observed versus predicted decile results were similar when we repeated these analyses, predicting a less stringent remission definition that included mild symptoms (ie, MADRS<10 and YMRS<7) at 1-year follow-up.
DISCUSSION
This is the first contemporary study examining the feasibility of predicting longitudinal outcomes in bipolar disorder using a national cohort. Recently, Houston et al conducted post hoc analyses to examine whether one could predict outcomes at 6 weeks in a more homogeneous sample of bipolar disorder patients-those participating in a randomized clinical trial who were divalproex treatment resistant and in a mixed state-based on early symptomatic response to treatment. 26 It is notable that our 1-year accuracy results in the gold standard and limited-detail models were comparable or higher than the AUCs in the Houston et al 26 study, despite differences in our populations and analytic design.
Our clinically detailed models were not statistically different in their predictive accuracy at 1-year follow-up compared with models with more limited detail and similar to the kind of information currently available in administrative data. However, the clinically detailed models did have higher accuracy at baseline than the limited-detail models. Moreover, calibration, as measured by agreement between predicted and observed values, varied by the type of data (clinically detailed or limited detail) and timing (baseline or 1-year). Clearly, our results speak to the limits of claims data for these purposes, but also the clinically detailed models did not fare better in this regard. It will be important for future study to develop predictive models that can improve upon the accuracy that we observe here.
There are several limitations to consider when interpreting these results. There was significant loss to follow-up of the study participants in this longitudinal study. We assumed that this loss to follow-up was missing at random after conditioning on the demographic, clinical, and treatment data although it is possible that this is not the case. If loss to follow-up depends on any unobservable characteristics after accounting for observable covariates and subjectspecific random effect, then our predicted outcomes are subject to a selection bias. Our data reflect the predictability of bipolar disorder outcomes for individuals who remain in treatment, which is a useful endeavor as it more closely approximates usual care (eg, a cohort in which persons drop out of treatment). Given the chronic and relapsing nature of bipolar disorder, the ability to predict outcomes for patients who remain in treatment has important clinical and policy relevance.
Although the STEP-BD naturalistic arm was designed to include a broader population than is usually seen in clinical trials, and treatment choices were not constrained, STEP-BD patients and treatment differ from those in usual care populations in several ways, as noted earlier. For example, the use of a structured interview by STEP-BD for the diagnosis of bipolardisorder, which may be more accurate than what would be seen in usual care settings. Having said STEP-BD "limited-detail" data and true administrative data. For example, clinician report of a prescription and patient report of adherence may not be concordant with information on prescription fills found in administrative data. The literature on this is mixed. Patients may overstate adherence, which may not be detected by clinicians. 28 However, patient self-report of adherence has also been associated with serum concentration in patients with bipolar disorder and schizophrenia, 29 and antidepressant prescription dispensing gaps in administrative data. 30 Discrepancies in demographic information are possible between administrative and self-report data; however, research supports that racial/ethnic misclassification of whites, blacks, and Hispanics in administrative data versus self-report does not appreciably bias estimates of racial/ethnic treatment utilization. [31] [32] [33] Although it is generally accepted that age and sex would be concordant between self-report and administrative data, we were unable to find prior literature specifically comparing these characteristics between the 2 data sources. Finally, differences in comorbid diagnosis detection in STEP-BD and usual care could have implications for the accuracy of administrative data in predicting bipolar outcomes. For example, STEP-BD treating clinicians identified a higher prevalence of SUD (privately insured = 34%, Medicaid insured = 38%) than in some prior administrative data studies (privately insured 3% and 8%; Medicaid 24%), [34] [35] [36] [37] and more consistent with prior literature on the comorbid SUD prevalence in bipolar disorder outpatient populations. 38, 39 Our study provides a starting point for predicting bipolar disorder outcomes. Future efforts will need to build upon our results to be useful for clinical or population health management purposes. Another important finding relates to the data available in claims datasets. First, the administrative data were inadequate for these purposes, so too were data containing more clinically detailed and nuanced information. Our results have important implications for the current feasibility of using demographic and health data in information exchanges for predicting bipolar disorder outcomes, as even detailed clinical data that would require a significant financial investment to obtain electronically were inadequate for predicting longitudinal bipolar disorder outcomes.
